Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — FY 2024 Earnings Presentation
22 slides from Zealand Pharma A/s's earnings presentation, Feb 20, 2025
Slide 1: FY 2024 Presentation
FY 2024 Presentation Zealand Pharma February 20, 2025 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: Agenda
Agenda Q&A Opening remarks R&D pipeline Financials Adam Steensberg David Kendall Henriette Wennicke Chief Executive Chief Medical Chief Financial Officer Officer Officer 3
Slide 4: Significant progress across obesity pipeline in 2024
Significant progress across obesity pipeline in 2024 Petrelintide Dapiglutide Survodutidea (amylin analog) (dual GLP-1/GLP-2 receptor agonist) (dual GCG/GLP-1 receptor agonist) Presented encouraging weight loss Reported positive topline data from Breakthrough Therapy Designation and tolerability dat
Slide 5: Strong focus in 2025 on advancing differentiated obesity programs in Phase 2 and 3
We have a strong focus in 2025 on advancing our differentiated obesity programs in Phase 2 and 3 Petrelintide Dapiglutide Survodutideb (amylin analog) (GLP-1R/GLP-2R) (GCGR/GLP-1R) Complete Ph2b obesity triala Report topline data from (ZUPREME-1) 28-week Ph1b trial Complete Ph3 obesity trialsc Initi
Slide 6: The obesity pandemic represents one of the greatest healthcare challenges of our time
The obesity pandemic represents one of the greatest healthcare challenges of our time Early days in the evolution of this market… For 300,000 years, human beings maintained a relatively stable BMI… Eligible patients in the US receiving ~2% prescriptions for weight loss therapy2 The obesity pandemic
Slide 7: GLP-1RA-based therapies are effective at reducing weight but are associated with GI tolerability issues
GLP-1RA-based therapies are effective at reducing weight but are associated with GI tolerability issues1 Target product profile of petrelintide holds potential to address the needs of patients and physicians Today, two QW GLP-1RA-based therapies are Petrelintide is a long-acting amylin analog with t
Slide 8: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Petrelintide (amylin analog) related comorbidities Obesity Obesity and Dapiglutide (GLP-1R/GLP-2R dual agonist) Obesity ZP6590 (GIP recepto
Slide 9: Petrelintide has consistently shown best-in-class potential across early clinical trials to date
Obesity Petrelintide Petrelintide has consistently shown best-in-class potential across early clinical trials to date MAD trial Part 1 MAD trial Part 2 SAD trial1 (6-week study)2 (16-week study)3 % change in body weight % change in body weight % change in body weight from baseline at Day 7 from base
Slide 10: Continuing development of petrelintide as monotherapy through Phase 2b trial (ZUPREME-1)
Obesity Petrelintide Continuing development of petrelintide as monotherapy through a comprehensive Phase 2b trial (ZUPREME-1) A randomized, double-blind, placebo-controlled, Phase 2b trial with petrelintide was initiated in Dec-20241,2 Aim: to evaluate change in body weight with multiple doses of pe
Slide 11: Expanding the development program with Phase 2b trial in obesity and T2D (ZUPREME-2)
Obesity Petrelintide Expanding the development program with Phase 2b trial in people with overweight/obesity and T2D (ZUPREME-2) A randomized, double-blind, placebo-controlled, Phase 2b trial with petrelintide to be initiated in H1 20251 Aim: Demonstrate superior weight loss for petrelintide vs. pla
Slide 12: We expect to report topline results with dapiglutide from the 28-week Phase 1b trial
Obesity Dapiglutide We expect to report topline results with dapiglutide from the 28-week Phase 1b trial in H1 2025… Phase 1b trial Part 1: Topline results1 Phase 1b trial Part 2: Topline results in H1 20252 Mean placebo-adjusted weight loss of up to 8.3% after 13 weeks • Includes a higher dose coho
Slide 13: Initiate a comprehensive Phase 2b trial with dapiglutide in H1 2025
Dapiglutide Obesity Dapiglutide …and initiate a comprehensive Phase 2b trial with dapiglutide in people with overweight/obesity in H1 2025 A randomized, double-blind, placebo-controlled, Phase 2b trial with dapiglutide to be initiated in H1 20251 Aim: To evaluate change in body weight with multiple
Slide 14: Survodutide shows best-in-class potential in MASH Phase 2 trial and is now in Phase 3
MASH Survodutide Survodutidea shows best-in-class potential in MASH Phase 2 trial and is now in large Phase 3 program 48-week biopsy-driven Phase 2 trial in MASH1 Phase 3 program in MASH has been initiated3 Improvement in liver fibrosis with no worsening of MASH LIVERAGE4 Paired biopsy results (F2/F
Slide 15: We remain committed to bring our rare disease programs to patients as soon as possible
Rare diseases We remain committed to bring our rare disease programs to patients as soon as possible Dasiglucagon: Congenital hyperinsulinism Glepaglutide: Short bowel syndrome Timing of next steps contingent on third-party Type-A meeting with the U.S. FDA expected manufacturing facility receiving a
Slide 16: Advancing early-stage pipeline with Kv1.3 inhibitor ZP9830
Inflammation ZP9830 Advancing early-stage pipeline through ongoing first- in-human clinical trial with Kv1.3 inhibitor ZP9830 ZP9830 is a potent and selective Kv1.3 inhibitor First-in-human SAD clinical trial2 The first-in-human Phase 1 single ascending dose trial include Kv1.3 is highly expressed i
Slide 17: FY 2024 Profit & Loss
FY 2024 Profit & Loss DKK million FY 2024 FY 2023 P&L reflecting Zealand’s investments in its differentiated assets targeting obesity Revenue 63 343 • Revenue of DKK 63 million is mainly driven by the license and Gross profit 55 324 development agreement with Novo Nordisk for Zegalogue®. Research an
Slide 18: Strong cash position of DKK 9.0 billion enables significant investments in our obesity programs
Strong cash position of DKK 9.0 billion enables significant investments in our obesity programs Secured cash of DKK 8.6 billion in 2024 through capital raises and the EIB loan facilitya DKK million 9,022 480 6,789 8,542 1,633 373 449 -931 1,427 1,184 -269 Cash position Cash flow from Other cash Net
Slide 19: 2025 financial guidance
2025 financial guidance 2025 operating expenses anticipated to be in the range of DKK 2,000-2,500 million Anticipated increase in OPEX is mainly to support mid-stage obesity pipeline and further enhance research efforts • Development: Accelerate investments in obesity pipeline, which in 2025 will in
Slide 20: Advancing for a sustainable future
Advancing for a sustainable future Highlights and ambitions Launched dedicated sustainability strategy, significantly increasing our efforts Notable organizational growth while maintaining high employee engagement and low turnover Calculated CO2 emissions and developed transition plan, with commitme
Slide 21: Exciting news flow with many potential catalysts in 2025
Exciting news flow with many potential catalysts in 2025 NON-EXHAUSTIVE H1 2025 H2 2025 Petrelintide Petrelintide Complete enrollment in Ph2b trial (overweight/obesity without T2D) Initiate Ph1b combination trial with GLP-1RA Petrelintide Survodutidea Initiate Ph2b trial (overweight/obesity with T2D
Slide 22: Q&A
Q&A Adam Steensberg David Kendall Henriette Wennicke Eric Cox Chief Executive Chief Medical Chief Financial Chief Commercial Officer Officer Officer Officer 22